Restricted accessResearch articleFirst published online 2020-09
Assessment of PPARGC1A,PPARGC1B,and PON1 Genetic Polymorphisms in Esophageal Squamous Cell Carcinoma Susceptibility in the Eastern Chinese Han Population: A Case–Control Study Involving 2351 Subjects
Previous studies suggested that alterations in the energy metabolism might be underlying cancer initiation and progression. Polymorphisms of genes involved in energy metabolism regulation, such as peroxisome proliferator-activated receptor gamma coactivator 1α (PPARGC1A), -β (PPARGC1B), and paraoxonase 1 (PON1), might confer susceptibility to esophageal squamous cell carcinoma (ESCC) and partially explain its pathogenesis. We investigated the effects of several single nucleotide polymorphisms (SNPs) in three metabolic-related genes (e.g., PPARGC1A, PPARGC1B, and PON1) on ESCC susceptibility. In total, 829 patients with sporadic ESCC and 1522 nontumor controls were enrolled in the study. SNPs were genotyped using PCR-ligase detection reaction. Our study revealed that the PPARGC1A rs3736265 G/A SNP significantly increased the risk for ESCC (GA vs. GG: adjusted odds ratio [OR] = 1.25, 95% confidence interval [95% CI] = 1.02–1.54, p = 0.034; GA+AA vs. GG: adjusted OR = 1.25, 95% CI = 1.03–1.52, p = 0.027]. In addition, a stratified analysis revealed that the PPARGC1A rs3736265 SNP was correlated with the development of ESCC in male and nondrinking subgroups. We also confirmed that the PPARGC1B rs17572019 G/A SNP promoted the risk of ESCC in subgroup with high alcohol intake. The PPARGC1A rs8192678 C/T polymorphism decreased the susceptibility of ESCC in men. These findings highlight that polymorphisms in PPARGC1A and PPARGC1B may contribute to ESCC susceptibility. In the future, further well-designed epidemiological studies are needed to confirm our findings.
Get full access to this article
View all access options for this article.
References
1.
AbeM., XieW., ReganM.M., KingI.B., StampferM.J., KantoffP.W., et al. (2011). Single-nucleotide polymorphisms within the antioxidant defence system and associations with aggressive prostate cancer. BJU Int, 107, 126–134.
2.
AhmedN.S., ShafikN.M., ElraheemO.A., and Abou-ElnoemanS.E. (2015). Association of paraoxonase-1(Q192R and L55M) gene polymorphisms and activity with colorectal cancer and effect of surgical intervention. Asian Pac J Cancer Prev, 16, 803–809.
3.
Aksoy-SagirliP., CakmakogluB., IsbirT., Kaytan-SaglamE., KizirA., TopuzE., et al. (2011). Paraoxonase-1 192/55 polymorphisms and the risk of lung cancer in a Turkish population. Anticancer Res, 31, 2225–2229.
4.
AntognelliC., Del BuonoC., LudoviniV., GoriS., TalesaV.N., CrinoL., et al. (2009). CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for breast cancer: an Italian case-control study. BMC Cancer 9,115.
5.
AntognelliC., MeariniL., TalesaV.N., GiannantoniA., and MeariniE. (2005). Association of CYP17, GSTP1, and PON1 polymorphisms with the risk of prostate cancer. Prostate, 63, 240–251.
6.
ArpaciA., GormusU., DalanB., BerkmanS., and IsbirT. (2009). Investigation of PON1 192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish population. In vivo (Athens, Greece), 23, 421–424.
7.
BhallaK., HwangB.J., DewiR.E., OuL., TwaddelW., FangH.B., et al. (2011). PGC1alpha promotes tumor growth by inducing gene expression programs supporting lipogenesis. Cancer Res, 71, 6888–6898.
8.
BostF., and KaminskiL. (2019). The metabolic modulator PGC-1alpha in cancer. Am J Cancer Res, 9, 198–211.
9.
BrayF., FerlayJ., SoerjomataramI., SiegelR.L., TorreL.A., and JemalA. (2018). Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 68, 394–424.
10.
CaiF.F., XuC., PanX., CaiL., LinX.Y., ChenS., et al. (2016). Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer. Oncotarget, 7, 77793–77806.
11.
CantoP., GranadosJ.B., Feria-BernalG., Coral-VazquezR.M., Garcia-GarciaE., TejedaM.E., et al. (2017). PPARGC1A and ADIPOQ polymorphisms are associated with aggressive prostate cancer in Mexican-Mestizo men with overweight or obesity. Cancer Biomark, 19, 297–303.
12.
ChangJ., ZhongR., TianJ., LiJ., ZhaiK., KeJ., et al. (2018). Exome-wide analyses identify low-frequency variant in CYP26B1 and additional coding variants associated with esophageal squamous cell carcinoma. Nature Genet, 50, 338–343.
13.
ChenL., LuW., FangL., XiongH., WuX., ZhangM., et al. (2016a). Association between L55M polymorphism in Paraoxonase 1 and cancer risk: a meta-analysis based on 21 studies. Oncotargets Ther, 9, 1151–1158.
14.
ChenW., ZhengR., BaadeP.D., ZhangS., ZengH., BrayF., et al. (2016b). Cancer statistics in China, 2015. CA Cancer J Clin, 66, 115–132.
15.
ChengC.F., KuH.C., and LinH. (2018). PGC-1alpha as a pivotal factor in lipid and metabolic regulation. Int J Mol Sci 19,3447.
16.
de Andrade BarretoE., de Souza SantosP.T., BergmannA., de OliveiraI.M., Wernersbach PintoL., BlancoT., et al. (2016). Alterations in glucose metabolism proteins responsible for the Warburg effect in esophageal squamous cell carcinoma. Exp Mol Pathol, 101, 66–73.
17.
DouglasH., and RobertA.W. (2011). Hallmarks of cancer: the next generation. Cell, 144, 646–674.
18.
EomS.Y., YimD.H., LeeC.H., ChoeK.H., AnJ.Y., LeeK.Y., et al. (2015). Interactions between paraoxonase 1 genetic polymorphisms and smoking and their effects on oxidative stress and lung cancer risk in a Korean population. PLoS One 10,e0119100.
19.
FranksP.W., ChristophiC.A., JablonskiK.A., BillingsL.K., DelahantyL.M., HortonE.S., et al. (2014). Common variation at PPARGC1A/B and change in body composition and metabolic traits following preventive interventions: the Diabetes Prevention Program. Diabetologia, 57, 485–490.
20.
Gonzalez-HerreraL., Gamas-TrujilloP.A., Medina-EscobedoG., Oaxaca-CastilloD., Perez-MendozaG., Williams-JacquezD., et al. (2015). The paraoxonase 1 gene c.-108C>T SNP in the promoter is associated with risk for glioma in Mexican patients, but not the p.L55M or p.Q192R polymorphisms in the coding region. Genet Test Mol Biomark, 19, 494–499.
21.
HusseinY.M., GharibA.F., EtewaR.L., and ElSawyW.H. (2011). Association of L55M and Q192R polymorphisms in paraoxonase 1 (PON1) gene with breast cancer risk and their clinical significance. Mol Cell Biochem, 351, 117–123.
22.
KnuttiD., KresslerD., and KralliA. (2001). Regulation of the transcriptional coactivator PGC-1 via MAPK-sensitive interaction with a repressor. Proc Natl Acad Sci U S Am, 98, 9713–9718.
23.
LiJ.D., FengQ.C., QiY., CuiG., and ZhaoS. (2017). PPARGC1A is upregulated and facilitates lung cancer metastasis. Exp Cell Res, 359, 356–360.
24.
LubinJ.H., CookM.B., PandeyaN., VaughanT.L., AbnetC.C., GiffenC., et al. (2012). The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol, 36, 306–316.
25.
Martinez-NavaG.A., Burguete-GarciaA.I., Lopez-CarrilloL., Hernandez-RamirezR.U., Madrid-MarinaV., and CebrianM.E. (2013). PPARgamma and PPARGC1B polymorphisms modify the association between phthalate metabolites and breast cancer risk. Biomarkers, 18, 493–501.
26.
MastorikouM., MacknessM., and MacknessB. (2006). Defective metabolism of oxidized phospholipid by HDL from people with type 2 diabetes. Diabetes, 55, 3099–3103.
27.
McGuirkS., GravelS.P., DebloisG., PapadopoliD.J., FaubertB., WegnerA., et al. (2013). PGC-1alpha supports glutamine metabolism in breast cancer. Cancer Metab 1,22.
28.
MerrimanT., and TerkeltaubR. (2017). PPARGC1B: insight into the expression of the gouty inflammation phenotype PPARGC1B and gouty inflammation. Rheumatology (Oxford, England), 56, 323–325.
29.
MoritaM., KumashiroR., KuboN., NakashimaY., YoshidaR., YoshinagaK., et al. (2010). Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int J Clin Oncol, 15, 126–134.
30.
Navarro SilveraS.A., MayneS.T., GammonM.D., VaughanT.L., ChowW.H., DubinJ.A., et al. (2014). Diet and lifestyle factors and risk of subtypes of esophageal and gastric cancers: classification tree analysis. Ann Epidemiol, 24, 50–57.
31.
OkadaE., UkawaS., NakamuraK., HirataM., NagaiA., MatsudaK., et al. (2017). Demographic and lifestyle factors and survival among patients with esophageal and gastric cancer: the Biobank Japan Project. J Epidemiol, 27, S29–s35.
32.
OzturkO., KagniciO.F., OzturkT., DurakH., TuzunerB.M., KisakesenH.I., et al. (2009). 192R allele of paraoxanase 1 (PON1) gene as a new marker for susceptibility to bladder cancer. Anticancer Res, 29, 4041–4046.
33.
PetrM., StastnyP., ZajacA., TufanoJ. J. and Maciejewska-SkrendoA. (2018). The role of peroxisome proliferator-activated receptors and their transcriptional coactivators gene variations in human trainability: a systematic review. Int J Mol Sci 19,1472.
34.
Pineda-BelmontesC.P., Hernandez-RamirezR.U., Hernandez-AlcarazC., CebrianM.E., and Lopez-CarrilloL. (2016). Genetic polymorphisms of PPAR gamma, arsenic methylation capacity and breast cancer risk in Mexican women. Salud Publ Mex, 58, 220–227.
35.
Primo-ParmoS.L., SorensonR.C., TeiberJ., and La DuB.N. (1996). The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Genomics, 33, 498–507.
36.
RainwaterD.L., RutherfordS., DyerT.D., RainwaterE.D., ColeS.A., VandebergJ.L., et al. (2009). Determinants of variation in human serum paraoxonase activity. Heredity, 102, 147–154.
37.
SaadatM. (2012). Paraoxonase 1 genetic polymorphisms and susceptibility to breast cancer: a meta-analysis. Cancer Epidemiol, 36, e101–e103.
38.
SehitogullariA., AslanM., SayirF., KahramanA., and DemirH. (2014). Serum paraoxonase-1 enzyme activities and oxidative stress levels in patients with esophageal squamous cell carcinoma. Redox Rep, 19, 199–205.
39.
St-PierreJ., DroriS., UldryM., SilvaggiJ.M., RheeJ., JagerS., et al. (2006). Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell, 127, 397–408.
40.
StevensV.L., RodriguezC., PavluckA.L., ThunM.J., and CalleE.E. (2006). Association of polymorphisms in the paraoxonase 1 gene with breast cancer incidence in the CPS-II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev, 15, 1226–1228.
41.
StevensV.L., RodriguezC., TalbotJ.T., PavluckA.L., ThunM.J., and CalleE.E. (2008). Paraoxonase 1 (PON1) polymorphisms and prostate cancer in the CPS-II Nutrition Cohort. Prostate, 68, 1336–1340.
42.
WangH., LiL., DingL., ZhangZ., and PuC. (2012). Association of genetic polymorphisms in the paraoxonase 1 gene with the risk and prognosis of non-small cell lung cancer in Chinese Han population. J Invest Med, 60, 592–597.
43.
WirtenbergerM., TchatchouS., HemminkiK., SchmutzhardJ., SutterC., SchmutzlerR.K., et al. (2006). Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. Carcinogenesis, 27, 2201–2208.
44.
ZhangS., JiangJ., ChenZ., WangY., TangW., ChenY., et al. (2018). Relationship of PPARG, PPARGC1A, and PPARGC1B polymorphisms with susceptibility to hepatocellular carcinoma in an eastern Chinese Han population. Oncotargets Ther, 11, 4651–4660.
ZhaoP., ZhaoL., ZouP., LuA., LiuN., YanW., et al. (2012). Genetic oxidative stress variants and glioma risk in a Chinese population: a hospital-based case-control study. BMC Cancer 12,617.
47.
ZhuM.L., YuH., ShiT.Y., He, j., WangM.Y., LiQ.X., et al. (2013). Polymorphisms in mTORC1 genes modulate risk of esophageal squamous cell carcinoma in eastern Chinese populations. J Thorac Oncol, 8, 788–795.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
